Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Stock Information for Adial Pharmaceuticals Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adial Pharmaceuticals Inc

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.